Proteostasis and AveXis test the troubled IPO waters as biotech valuations wane

Damian Garde A pair of early-stage biotech companies has joined the thinning queue of drug developers trying to go public amid a painful market correction, angling to raise more than ...

Replacing a biotech legend, Gilead’s new CEO inherits sky-high expectations

Damian Garde John Martin, the man who led Gilead Sciences from the basements of biotech to the verge of Big Pharma, is stepping down after 20 years, with longtime lieutenant John Milligan ...

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program ...

CRISPR biotech Intellia leases a big R&D hub in Cambridge, MA

Damian Garde Intellia Therapeutics, a Novartis-backed biotech working on gene-editing technology, leased a sizable research space in the hotbed of Cambridge, MA. FierceBiotech News

Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent

John Carroll FierceBiotech News

Biotech rehearses its ‘difficult’ second album at #JPM16

Damian Garde The two most commonly watched indexes of biotech stocks have each fallen more than 35% from their July peaks, battered down by a pervasive sense that the frothy days of ...

Biotech has a problem with women? Or is it the other way around?

John Carroll FierceBiotech News

Accelerator’s second NYC biotech startup sets out with $17M and some Gates-backed science

Damian Garde Accelerator, among the financiers looking to kick-start a fledgling biotech hub in New York City, launched its second local project in the form of Lodo Therapeutics, a ...

OrbiMed rings up $950M for its transatlantic biotech Fund VI

John Carroll OrbiMed has come through with a whopping $ 950 million biotech venture fund, committing anywhere from $ 10 million to a hefty $ 75 million to each of about 30 new companies. FierceBiotech ...

Novartis backs $176M microbiome biotech fund

John Carroll Novartis has stepped in to back Paris-based Seventure Partners' biotech fund focused exclusively on the emerging field of the microbiome as well as nutrition, bringing ...

Sofinnova Partners launches a €300M biotech startup fund with a transatlantic focus

John Carroll PARIS–Sofinnova Partners has reloaded its cash reserves and started to build the next wave of 15 to 20 biotechs for its portfolio. The venture group has wrapped a ...

Mesoblast disappoints in another below-the-range biotech IPO

Damian Garde Australian biotech Mesoblast priced its U.S. IPO below expectations, raising $ 60 million to support its pipeline of cell therapies. FierceBiotech News
Page 1 of 1812345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS